Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has provided an update.
On August 18, 2025, Smith & Nephew plc announced the partial vesting of awards under its Restricted Share Plan 2024, with some shares sold to cover tax obligations. Additionally, David King, a Non-Executive Director, purchased American Depository Receipts on the New York Stock Exchange, reflecting confidence in the company’s market position.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company that specializes in the development and manufacturing of advanced medical devices. The company focuses on providing solutions in areas such as orthopedics, sports medicine, and wound management, serving healthcare professionals and patients worldwide.
Average Trading Volume: 981,389
Technical Sentiment Signal: Buy
Current Market Cap: $15.84B
Learn more about SNN stock on TipRanks’ Stock Analysis page.